drugset
drugset / Trial / NCT01717846

Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis

NCT01717846 ↗

Phase 4 Withdrawn University of California, Los Angeles Bristol-Myers Squibb · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This proposal will test the hypothesis that Orencia affects apoptosis and apoptosis related genes/biomarkers in vivo in rheumatoid arthritis (RA) patients.

Timeline

Start
2012-12
Primary completion
2013-11
Completion
2014-11

Outcome

Outcome not reported

Stopped: “The PI has left UCLA and we do not plan to pursue this study.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 125 mg Subcutaneous

Indications

rheumatoid arthritis